Abstract
Innovative therapies for chronic myelogenous leukemia (CML) have focused mainly on combining autologous transplantation with another modality of therapy for purging of the graft or treatment of the patient after transplant. Of the three categories of innovative therapies, two are based on studies that demonstrate the bcr/abl gene rearrangement in the pathogenesis of CML, whereas the third is based on the observation that allogeneic disparity is important to maintain remissions in CML. The rationale and data supporting these innovative approaches are reviewed in this article and future strategies are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 173-206 |
| Number of pages | 34 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 12 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1998 |
